Pfizer and biontech report new data on omicron ba.4/ba.5-adapted bivalent booster demonstrating improved immune response against emerging omicron sublineages

New york and mainz, germany, november 18, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced results from an analysis examining the immune response induced by their omicron ba.4/ba.5-adapted bivalent covid-19 vaccine [pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5)] against newer omicron sublineages, including ba.4.6, ba.2.75.2, bq.1.1 and xbb.1. these data, posted on the preprint server biorxiv , indicate that the companies' bivalent vaccine elicits a greater increase in neutralizing antibody titers than the companies' original covid-19 vaccine against these emerging omicron sublineages. based on these findings, the omicron ba.4/ba.5-adapted bivalent booster may help to provide improved protection against covid-19 due to omicron ba.4 and ba.5 sublineages as well as new sublineages that continue to increase in prevalence.
BNTX Ratings Summary
BNTX Quant Ranking